Expression of the β chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies

The idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases characterized by chronic lymphocytic and macrophagic infiltration in muscle. Because the mechanism for recruitment of these cells probably involves chemokines, we focused on the study of the expression pattern of some β chemokines and receptors because it may provide a basis for selective immunotherapy. The expression of CCL3 (MIP‐1α), CCL4 (MIP‐1β), CCL5 (RANTES) and their main receptors (CCR1 and CCR5) was studied by semi‐quantitative reverse transcriptase polymerase chain reaction (RT‐PCR) and immunohistochemistry in a series of 16 IIM and five controls (four normal muscles and one tonsil). Except for CCL5, strong expression was observed by RT‐PCR with all molecules in all IIM subtypes in comparison to control muscle. Immunohistochemistry revealed diffuse CCL4 expression in all vessels in dermatomyositis. In both polymyositis and sporadic inclusion body myositis (s‐IBM) it was restricted to vessels in the vicinity of inflammatory exudates. CCL5 expression was low, restricted to a few inflammatory cells in all IIM; CCR1 expression was mainly restricted to macrophages and s‐IBM endothelial cells, whereas CCR5 was localized in inflammatory cells invading non‐necrotic muscle fibres. Expressions of both receptors were also recorded in few muscle fibres. In conclusion, the upregulation of β chemokines and receptors in IIM and their differential expression by various cells may contribute to chronic inflammation and to the peculiar distribution of inflammatory exudates in these diseases.

[1]  Paolo Confalonieri,et al.  Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features , 1997, Journal of Neurology.

[2]  M. Dalakas.  The molecular and cellular pathology of inflammatory muscle diseases. , 2001, Current opinion in pharmacology.

[3]  U. Andersson,et al.  Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. , 1997, Arthritis and rheumatism.

[4]  R. de Waal Malefyt,et al.  Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. , 2000, International immunology.

[5]  K. Nagaraju.  Update on immunopathogenesis in inflammatory myopathies , 2001, Current opinion in rheumatology.

[6]  A. Engel,et al.  Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis , 1984, Annals of neurology.

[7]  L. Daniel,et al.  Expression des molécules d'adhésion dans les myopathies inflammatoires idiopathiques : Etude immunohistochimique de 17 cas , 1999 .

[8]  J. Mendell,et al.  Microvascular deposition of complement membrane attack complex in dermatomyositis. , 1986, The New England journal of medicine.

[9]  D. Figarella-Branger,et al.  Inflammatory and non-inflammatory inclusion body myositis , 1990, Acta Neuropathologica.

[10]  W. Engel,et al.  Inclusion‐Body Myositis: Newest Concepts of Pathogenesis and Relation to Aging and Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.

[11]  Y. Pouliot,et al.  Expression of immunoreactive major histocompatibility complex products in human skeletal muscles , 1988, Annals of neurology.

[12]  Klaus Ley,et al.  Chemokines and chemokine receptors in leukocyte trafficking. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[13]  Z. Brown,et al.  Chemokine Receptors , 2006, Treatments in respiratory medicine.

[14]  A. Engel,et al.  Expression of Cell Adhesion Molecules in Inflammatory Myopathies and Duchenne Dystrophy , 1994, Journal of neuropathology and experimental neurology.

[15]  S. Mummidi,et al.  The Human CC Chemokine Receptor 5 (CCR5) Gene , 1997, The Journal of Biological Chemistry.

[16]  R. Mantegazza,et al.  Increased Expression of β‐Chemokines in Muscle of Patients with Inflammatory Myopathies , 2000, Journal of neuropathology and experimental neurology.

[17]  C. Mackay,et al.  Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. , 1997, Science.

[18]  A. Engel,et al.  Immunocytochemical study of CD45 T cell isoforms in inflammatory myopathies. , 1995, The American journal of pathology.

[19]  M. Aurrand-Lions,et al.  The parting of the endothelium: miracle, or simply a junctional affair? , 2000, Journal of cell science.

[20]  K. thestrup-pedersen,et al.  Eotaxin activates T cells to chemotaxis and adhesion only if induced to express CCR3 by IL-2 together with IL-4. , 1999, Journal of immunology.

[21]  F. Miller,et al.  Idiopathic inflammatory muscle disease: clinical aspects. , 2000, Bailliere's best practice & research. Clinical rheumatology.

[22]  J. Schröder,et al.  Differential expression of chemokines in inflammatory myopathies , 2002, Neurology.

[23]  S. Carpenter,et al.  Pathology of the inflammatory myopathies. , 1993, Bailliere's clinical neurology.

[24]  A. Luster,et al.  Chemokines--chemotactic cytokines that mediate inflammation. , 1998, The New England journal of medicine.

[25]  M. Baggiolini,et al.  Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes , 1996, The Journal of experimental medicine.

[26]  Robert G. Cooper,et al.  Polymyositis and Dermatomyositis , 2022 .

[27]  D. Figarella-Branger,et al.  CCR2A and CCR2B, the two isoforms of the monocyte chemoattractant protein-1 receptor are up-regulated and expressed by different cell subsets in idiopathic inflammatory myopathies , 2001, Acta Neuropathologica.

[28]  M. Baggiolini,et al.  CCR5 is characteristic of Th1 lymphocytes , 1998, Nature.

[29]  A. Engel,et al.  Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. , 1986, Human pathology.

[30]  H. Lepidi,et al.  Local expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic inflammatory myopathies , 1999, Acta Neuropathologica.

[31]  Nagaraju,et al.  A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli , 1998, Clinical and experimental immunology.

[32]  Pellissier,et al.  Local expression of cytokines in idiopathic inflammatory myopathies , 1998, Neuropathology and applied neurobiology.

[33]  M. Dalakas,et al.  Inclusion body myositis and myopathies , 1997, Journal of the Neurological Sciences.

[34]  A. Oldfors,et al.  Inclusion body myositis: genetic factors, aberrant protein expression, and autoimmunity , 2001, Current opinion in rheumatology.

[35]  D. Figarella-Branger,et al.  Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies , 2003, Muscle & nerve.

[36]  P. Plotz,et al.  The predominance of beta (CC) chemokine transcripts in idiopathic inflammatory muscle diseases. , 1997, Proceedings of the Association of American Physicians.

[37]  J. Andersson,et al.  Regulation of CCR5 and CXCR4 expression by type 1 and type 2 cytokines: CCR5 expression is downregulated by IL-10 in CD4-positive lymphocytes. , 1999, Clinical immunology.

[38]  J. Gómez-Reino,et al.  Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. , 1999, Arthritis and rheumatism.

[39]  H. Goebel,et al.  Expression of cell adhesion molecules in inflammatory myopathies , 1995, Journal of Neuroimmunology.

[40]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975 .